September 7, 2007—Foster Wheeler Ltd. has announced that its Singapore subsidiary Foster Wheeler Eastern Private Limited, part of its Global Engineering and Construction Group, has been awarded an engineering, procurement, construction management and commissioning services contract by GlaxoSmithKline Biologicals for a new biotechnology production facility in Singapore.
This state-of-the-art facility includes two production buildings, a quality control and administration building, and a utilities building, all on a site of more than 8.8 hectares in Tuas Biomedical Park, in Singapore, says Foster Wheeler.
Foster Wheeler Asia Pacific credits its success in winning the contract to the performance of the Foster Wheeler team on GSK Biologicals’ new vaccine facility in Hungary, which is now complete, and its ability to leverage this successful experience for the new Singaporean facility. The company also points to its 30-year track record of delivering safe and successful projects in Singapore.
The value of the contract was not disclosed. For more information visit the Foster Wheeler Web site.
